Irreversible ototoxicity associated with difluoromethylornithine

Christopher D. Lao, Patricia Backoff, Lawrence I. Shotland, Deborah McCarty, Tracy Eaton, Frank G. Ondrey, Jaye L. Viner, Stuart Jon Spechler, Ernest T. Hawk, Dean E. Brenner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials. Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m2/d, and generally when the cumulative dose exceeds 250 g/m 2. In a recently completed Barrett's esophagus chemoprevention trial, a participant developed a 15-dB decrease in hearing at frequencies of 250, 2,000, and 3,000 Hz in the right ear and a ≥20-dB decrease in hearing at 4,000 to 6,000 Hz in the left ear after taking 0.5 g/m2/d DFMO for approximately 13 weeks (cumulative dose of 45 g/m2). The threshold shifts persisted 7 months after DFMO was discontinued. There was no obvious impact on the participant's clinical hearing, but these findings were consistent with irreversible hearing loss. This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk.

Original languageEnglish (US)
Pages (from-to)1250-1252
Number of pages3
JournalCancer Epidemiology Biomarkers and Prevention
Volume13
Issue number7
StatePublished - Jul 2004

Fingerprint

Eflornithine
Hearing
Hearing Loss
Ear
Clinical Trials
Barrett Esophagus
Chemoprevention
Polyamines
Cell Proliferation
Enzymes
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Lao, C. D., Backoff, P., Shotland, L. I., McCarty, D., Eaton, T., Ondrey, F. G., ... Brenner, D. E. (2004). Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiology Biomarkers and Prevention, 13(7), 1250-1252.

Irreversible ototoxicity associated with difluoromethylornithine. / Lao, Christopher D.; Backoff, Patricia; Shotland, Lawrence I.; McCarty, Deborah; Eaton, Tracy; Ondrey, Frank G.; Viner, Jaye L.; Spechler, Stuart Jon; Hawk, Ernest T.; Brenner, Dean E.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 13, No. 7, 07.2004, p. 1250-1252.

Research output: Contribution to journalArticle

Lao, CD, Backoff, P, Shotland, LI, McCarty, D, Eaton, T, Ondrey, FG, Viner, JL, Spechler, SJ, Hawk, ET & Brenner, DE 2004, 'Irreversible ototoxicity associated with difluoromethylornithine', Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 7, pp. 1250-1252.
Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG et al. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiology Biomarkers and Prevention. 2004 Jul;13(7):1250-1252.
Lao, Christopher D. ; Backoff, Patricia ; Shotland, Lawrence I. ; McCarty, Deborah ; Eaton, Tracy ; Ondrey, Frank G. ; Viner, Jaye L. ; Spechler, Stuart Jon ; Hawk, Ernest T. ; Brenner, Dean E. / Irreversible ototoxicity associated with difluoromethylornithine. In: Cancer Epidemiology Biomarkers and Prevention. 2004 ; Vol. 13, No. 7. pp. 1250-1252.
@article{3cd4411439384cb5b4b18051c5cfa5eb,
title = "Irreversible ototoxicity associated with difluoromethylornithine",
abstract = "Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials. Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m2/d, and generally when the cumulative dose exceeds 250 g/m 2. In a recently completed Barrett's esophagus chemoprevention trial, a participant developed a 15-dB decrease in hearing at frequencies of 250, 2,000, and 3,000 Hz in the right ear and a ≥20-dB decrease in hearing at 4,000 to 6,000 Hz in the left ear after taking 0.5 g/m2/d DFMO for approximately 13 weeks (cumulative dose of 45 g/m2). The threshold shifts persisted 7 months after DFMO was discontinued. There was no obvious impact on the participant's clinical hearing, but these findings were consistent with irreversible hearing loss. This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk.",
author = "Lao, {Christopher D.} and Patricia Backoff and Shotland, {Lawrence I.} and Deborah McCarty and Tracy Eaton and Ondrey, {Frank G.} and Viner, {Jaye L.} and Spechler, {Stuart Jon} and Hawk, {Ernest T.} and Brenner, {Dean E.}",
year = "2004",
month = "7",
language = "English (US)",
volume = "13",
pages = "1250--1252",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Irreversible ototoxicity associated with difluoromethylornithine

AU - Lao, Christopher D.

AU - Backoff, Patricia

AU - Shotland, Lawrence I.

AU - McCarty, Deborah

AU - Eaton, Tracy

AU - Ondrey, Frank G.

AU - Viner, Jaye L.

AU - Spechler, Stuart Jon

AU - Hawk, Ernest T.

AU - Brenner, Dean E.

PY - 2004/7

Y1 - 2004/7

N2 - Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials. Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m2/d, and generally when the cumulative dose exceeds 250 g/m 2. In a recently completed Barrett's esophagus chemoprevention trial, a participant developed a 15-dB decrease in hearing at frequencies of 250, 2,000, and 3,000 Hz in the right ear and a ≥20-dB decrease in hearing at 4,000 to 6,000 Hz in the left ear after taking 0.5 g/m2/d DFMO for approximately 13 weeks (cumulative dose of 45 g/m2). The threshold shifts persisted 7 months after DFMO was discontinued. There was no obvious impact on the participant's clinical hearing, but these findings were consistent with irreversible hearing loss. This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk.

AB - Difluoromethylornithine (DFMO) is a potent, irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the synthesis of polyamines that promote cellular proliferation. DFMO has been tested as a potential cancer therapeutic and chemopreventive agent in clinical trials. Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m2/d, and generally when the cumulative dose exceeds 250 g/m 2. In a recently completed Barrett's esophagus chemoprevention trial, a participant developed a 15-dB decrease in hearing at frequencies of 250, 2,000, and 3,000 Hz in the right ear and a ≥20-dB decrease in hearing at 4,000 to 6,000 Hz in the left ear after taking 0.5 g/m2/d DFMO for approximately 13 weeks (cumulative dose of 45 g/m2). The threshold shifts persisted 7 months after DFMO was discontinued. There was no obvious impact on the participant's clinical hearing, but these findings were consistent with irreversible hearing loss. This is the first case reported of irreversible ototoxicity in a clinical trial participant receiving DFMO and, thus, trial participants should be made aware of this small but important risk.

UR - http://www.scopus.com/inward/record.url?scp=3142681067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142681067&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1250

EP - 1252

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -